Clinical trials: Female Reproductive System Neoplasm
Ovarian Cancer, Ovary Neoplasm
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
A phase III prospective study with the primary objective to compare the efficacy and safety of HIPEC( Hyperthermic Intraperitoneal Chemotherapy).
- Conditions
- Ovarian Cancer, Ovary Neoplasm, Ovarian Neoplasms, Epithelial Ovarian Cancer
- Trial name
- HIPECOV (NCT03371693)
- Testing
- HIPEC, CRS, IVCT
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Zhongnan Hospital
Polycystic Ovary Syndrome
A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation
This is a Phase IV, prospective, observational, single arm, multicenter trial to identify the population at high risk of overstimulation associated with signs and symptoms of PCOS and examines the utility of 12.5 international…
- Trial name
- ARTIST (NCT02607293)
- Testing
- Gonal-f®, Long GnRH agonist, GnRH antagonist
- Where
- Germany
- Volunteers
- 1,064 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Uterine Cervical Neoplasm
Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples
The purpose of the study is to compare the results of the Becton Dickinson (BD) Human Papilloma Virus (HPV) Assay on the Viper LT instrument from Liquid-based cytology media diluted in HPV diluent to adjudicated histology results…
- Trial name
- NCT03020121
- Testing
- Colposcopy/biopsy
- Where
- 12 sites in United States, Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Becton, Dickinson and Company
Advanced Solid Tumors
Study of Intermittent OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.
- Trial name
- NCT00514306
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Astellas Pharma Inc
Ovarian Neoplasms
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
The purpose of this study is to determine if participants with platinum-refractory or platinum-resistant advanced ovarian cancer have a better outcome when treated with Olaratumab (IMC-3G3) in combination with Liposomal…
- Trial name
- NCT00913835
- Testing
- Olaratumab, liposomal doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 125 people
- Sponsor
- Eli Lilly and Company
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
This phase I trial tests the safety, side effects, best dose of MUC1-activated T cells in treating patients with ovarian cancer that has come back after a period of improvement (relapsed) or that remains despite treatment…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT06483048
- Testing
- Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Ovarian Neoplasm
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer
The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.
- Trial name
- ICEBERG 2 (NCT00494442)
- Testing
- KU-0059436 (AZD2281)(PARP inhibitor)
- Where
- 11 sites in United States, Australia and 3 more
- Volunteers
- 58 people
- Sponsor
- AstraZeneca
Vulvar Cancers, Vulva Neoplasm
Needlefree Lidocaine Application for Vulvar Biopsies
The goal of this study is to compare pain during a vulvar biopsy using either the needle-free J-Tip device or the standard lidocaine shot.
- Conditions
- Vulvar Cancers, Vulva Neoplasm, Vulvar Dysplasia
- Trial name
- NCT07793552
- Testing
- J-Tip, Lidocaine HCl 1%
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Tufts Medical Center
Endometrial Neoplasm Malignant
Identification and Characterization of Endometrial Cancer With Specific Tumor Markers in Serum and Endometrial Tissue
Endometrial cancer is the most common malignant tumor of the female genital tract in our means. The diagnosis is made by endometrial biopsy sampling with anatomopathological analysis which pinpoints the cell line and the level of…
- Trial name
- NCT03498924
- Testing
- Measure of biomarkers in serum and endometrial tissue
- Where
- Spain
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Fundación Investigación Sanitaria en León
Endometrial Cancer, Endometrial Neoplasm
Precision Medicine Applied to the Study of Endometrial Cancer: Application of NGS for Molecular Classification
In recent years, knowledge about cancer biology has expanded significantly. The study of gene expression profiles has revealed the heterogeneous nature and potential reclassification of the various tumor subtypes based on…
- Trial name
- NCT07006103
- Volunteers
- 400 people
- Sponsor
- Hospital Italiano de Buenos Aires
Cervical Intraepithelial Neoplasia
Imiquimod Treatment of CIN Lesions
Rationale: Cervical Intraepithelial Neoplasia (CIN) is the premalignant condition of cervical cancer. High grade CIN (CIN 2-3) is currently treated by large loop excision of the transformation zone (LLETZ).
- Trial name
- TOPIC (NCT02329171)
- Testing
- Imiquimod, LLETZ
- Where
- Netherlands
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Uterine Cervical Neoplasm
HPV Self-sampling for Underscreened Latinas
The goal of this study is to learn if women of Hispanic/Latina ethnicity are willing to self-collect a cervico-vaginal sample for HPV testing.
- Trial name
- NCT06439706
- Testing
- HPV Self-Sampling, Group Education
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Cancer of Cervix
Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients
The propose of this study is to determine if neoadjuvant chemotherapy followed by chemoradiation is safe and effective in locally advanced cervical cancer patients.
- Trial name
- NCT02309658
- Testing
- gemcitabine, cisplatin, chemoradiation
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Professor Fernando Figueira Integral Medicine Institute
Uterine Cervical Neoplasm, Uterine Neoplasm
Offering Cervical Cancer Screening to Older Women
This study evaluates the effect and feasibility of expanding the target population in the Danish cervical cancer screening program to include women aged 65 to 69 years.
- Conditions
- Uterine Cervical Neoplasm, Uterine Neoplasm, Uterine Cervical Disease, Mass Screening
- Trial name
- NCT04114968
- Testing
- GP-based screening or HPV self-sampling
- Where
- Denmark
- Volunteers
- 20,000 people
- Sponsor
- University of Aarhus
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
This phase I trial investigates the side effects and best dose of abexinostat and palbociclib when given together with fulvestrant in treating patients with breast or gynecologic cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT04498520
- Testing
- Abexinostat Tosylate, Fulvestrant, Palbociclib
- Sponsor
- Pamela Munster
Infertility, Ovulation Induction
SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women
Efficacy and safety studies in the past have suggested that a starting dose of 75 International Unit (IU) of SJ-0021, and an increase in the dose by 37.5 IU every 7 days, are safe for treatment of subjects with ovulatory…
- Trial name
- NCT01185782
- Testing
- Gonalef® (Follitropin alfa), Purified pituitary gonadotropin (Fertinorm-P®)
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
No Condition
Comparison of Clinical Outcomes Between IVM and Minimal Stimulation IVF in Patients With PCOS
Polycystic ovarian syndrome (PCOS) is most common endocrinologic disease in women of reproductive age with incidence of 6.6 ~ 8%.
- Trial name
- NCT03134482
- Testing
- IVM, Minimal stimulation IVF
- Where
- 2 sites in South Korea
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- CHA University
Anxiety Disorder, Cervical Cancer
Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer
This randomized pilot clinical trial studies the feasibility of a pre-operative and/or post-operative scripted sexual health informational intervention and how well it works in improving sexual function in patients with…
- Conditions
- Anxiety Disorder, Cervical Cancer, Endometrial Cancer, Female Reproductive Cancer
- Trial name
- NCT02096783
- Testing
- informational intervention, counseling intervention, questionnaire administration
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Wisconsin, Madison
Human Papillomavirus-Related Malignant Neoplasm
A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ
This is an open-label and triple cohort study of the safety and efficacy of TALEN and CRISPR/Cas9 to possibly treat HPV Persistency and human cervical intraepithelial neoplasiaⅠwithout invasion.
- Trial name
- NCT03057912
- Testing
- TALEN, CRISPR/Cas9
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University